Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 202-211 , July 2005

Treatment of Non-Hodgkin’s Lymphoma (NHL) With Radiolabeled Antibodies (mAbs)

  • Gerald L. DeNardo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Gerald L. DeNardo, MD, Radiodiagnosis and Therapy, University of California Davis Medical Center, 1508 Alhambra Blvd #3100, Sacramento, CA 95816.

References 

  1. Armitage JO . Treatment of non-Hodgkin’s lymphoma . N Engl J Med . 1993;328:1023–1030
  2. Fisher RI , Gaynor ER , Dahlberg S , et al.   Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma . N Engl J Med . 1993;328:1002–1006
  3. McLaughlin P , Grillo-Lopez AJ , Link BK , et al.   Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma (Half of patients respond to a four-dose treatment program) . J Clin Oncol . 1998;16:2825–2833
  4. Coiffer B , Lepage E , Briere J , et al.   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma . N Engl J Med . 2002;346:235–242
  5. Witzig TE , Gordon LI , Cabanillas F , et al.   Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma . J Clin Oncol . 2002;20:2453–2463
  6. Kaminski MS , Zelenetz AD , Press OW , et al.   Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas . J Clin Oncol . 2001;19:3918–3928
  7. Juweid M , Sharkey RM , Markowitz A , et al.   Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody . Cancer Res . 1995;55:5899s–5907s
  8. Juweid ME , Stadtmauer E , Hajjar G , et al.   Pharmacokinetics, dosimetry and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) . Clin Cancer Res . 1999;5:3292s–3303s
  9. DeNardo GL , DeNardo SJ , Lamborn KR , et al.   Low-dose fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody . Cancer Biother Radiopharm . 1998;13:239–254
  10. DeNardo GL , DeNardo SJ , Goldstein DS , et al.   Maximum tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma . J Clin Oncol . 1998;16:3246–3256
  11. Beierwaltes WH . Radioiodine-labeled compounds previously or currently used for tumor localization . Proceedings of an Advisory Group Meeting on Tumor Localization with Radioactive Agents. Panel Proceedings Series . Vienna, Austria: International Atomic Energy Agency; 1974; Agency IAE
  12. Ettinger DS , Dragon LH , Klein J , et al.   Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer. A case report . Cancer Treat Rep . 1979;63:131–134
  13. Kohler G , Milstein C . Continuous culture of fused cells secreting antibody of predefined specificity . Nature . 1975;256:495–497
  14. Carrasquillo JA , Krohn KA , Beaumier P , et al.   Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments . Cancer Treat Rep . 1984;68:317–328
  15. DeNardo SJ , DeNardo GL , O’Grady LF , et al.   Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies . Int J Biol Markers . 1987;2:49–53
  16. Nadler LM , Stashenko P , Hardy R , et al.   Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen . Cancer Res . 1980;40:3147–3154
  17. Miller RA , Maloney DG , Warnke R , et al.   Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody . N Engl J Med . 1982;306:517–522
  18. DeNardo SJ , DeNardo GL , O’Grady LF , et al.   Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody . Antibody Immunoconj Radiophar . 1988;1:17–33
  19. DeNardo GL , DeNardo SJ , O’Grady LF , et al.   Fractionated radioimmunotherapy of B-cell malignancies with 131I- Lym-1 . Cancer Res . 1990;50(suppl):1014–1016
  20. Press OW , Eary JF , Badger CC , et al.   Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody . J Clin Oncol . 1989;7:1027–1038
  21. Knox SJ . Radioimmunotherapy of the non-Hodgkin’s lymphomas . Semin Radiat Oncol . 1995;5:331–341
  22. Kaminski M , Tuck M , Regan D . High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar) . Blood . 2002;100:356a
  23. Press OW , Eary JF , Appelbaum FR , et al.   Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas . Lancet . 1995;346:336–340
  24. Witzig T , White C , Wiseman G , et al.   Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 B-cell non-Hodgkin’s lymphoma . J Clin Oncol . 1999;17:3793–3803
  25. Witzig TE , Flinn IW , Gordon LI , et al.   Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma . J Clin Oncol . 2002;20:3262–3269
  26. Wiseman GA , Leigh B , Erwin WD , et al.   Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma . Cancer . 2002;94:1349–1357
  27. Wiseman GA , Leigh B , Witzig T , et al.   Radiation exposure is very low to family members of patients treated with yttrium-90 Zevalin TM anti-CD20 monoclonal antibody therapy for lymphoma . Eur J Nucl Med . 2001;28:1198
  28. Wagner HN , Wiseman GA , Marcus CS , et al.   Administration guidelines for radioimmunotherapy of non-Hodgkin’s Lymphoma with 90Y-labeled anti-CD20 monoclonal antibody . J Nucl Med . 2002;43:267–272
  29. Witzig TE , White CA , Gordon LI . Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma . J Clin Oncol . 2003;21:1263–1270
  30. Vose JM , Colcher D , Gobar L , et al.   Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin’s lymphoma . Leuk Lymphoma . 2000;38:91–101
  31. Goldenberg DM , Horowitz JA , Sharkey RM , et al.   Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody . J Clin Oncol . 1991;9:548–564
  32. Sharkey RM , Brenner A , Burton J , et al.   RIT of non-Hodgkin’s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab) (Do tumor targeting and dosimetry predict therapeutic response?) . J Nucl Med . 2003;44:2000–2018
  33. Griffiths GL , Govindan SV , Sharkey RM , et al.   90Y-DOTA-hLL2 (An agent for radioimmunotherapy of non-Hodgkin’s lymphoma) . J Nucl Med . 2003;44:77–84
  34. Linden O , Tennvall J , Cavallin-Stahl E , et al.   Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas . Clin Cancer Res . 1999;5:3287s–3291s
  35. Linden O , Tennvall J , Cavallin SE , et al.   Durable response to 90Y-epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule . Blood . 2001;98:2524
  36. Postema EJ , Raemaekers JM , Oyen WJG , et al.   Final results of a phase I RIT trial using 186Re-Epratuzumab for the treatment of patients with non-Hodgkin’s lymphoma . Clin Cancer Res . 2003;9:3995s–4002s
  37. Juweid ME . Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma (From clinical trials to clinical practice) . J Nucl Med . 2002;43:1507–1529
  38. Dillman RO , Beauregard JC , Halpern SE , et al.   Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies . J Biol Response Modifiers . 1986;5:73–84
  39. Weiden PL , Breitz HB , Press O , et al.   Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL) (Initial phase I/II study results) . Cancer Biother Radiopharm . 2000;15:15–29
  40. DeNardo GL , Kukis DL , Shen S , et al.   67Cu-versus 131I-labeled Lym-1 antibody (Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin’s lymphoma) . Clin Cancer Res . 1999;5:533–541
  41. Liu C , DeNardo GL , Tobin E , et al.   Antilymphoma Effects of Anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells . Cancer Biother Radiopharm . 2004;19:545–561
  42. Leonard JP . Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (Epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (Apolizumab) . Semin Oncol . 2002;29:81–86
  43. Kukis DL , DeNardo GL , DeNardo SJ , et al.   Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates . Cancer Res . 1995;55:878–884
  44. DeNardo GL , Kroger LA , DeNardo SJ , et al.   Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3) . Cancer . 1994;73:1012–1022
  45. DeNardo GL , DeNardo SJ , Peterson JK , et al.   Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates . Clin Cancer Res . 2003;9(suppl):3865–3872
  46. Kaminski MS , Estes J , Zasadny KR , et al.   Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma (Updated results and long-term follow-up of the University of Michigan experience) . Blood . 2000;96:1259–1266
  47. Wiseman GA , White CA , Witzig TA , et al.   Final dosimetry results of IDEC-Y2B8 phase I/II 90Yttrium radioimmunotherapy trial on non-Hodgkin’s lymphoma (NHL) . J Nucl Med . 1999;40:64P
  48. DeNardo GL , Schlom J , Buchsbaum DJ , et al.   Rationales, evidence and design considerations in multiple dose (fractionated) radioimmunotherapy . Cancer . 2002;94:1332–1348
  49. DeNardo GL , DeNardo SJ , Kukis DL , et al.   Maximum tolerated dose of 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma (A pilot study) . Anticancer Res . 1998;18:2779–2788
  50. Meredith RF , Khazaeli MB , Liu T , et al.   Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer . J Nucl Med . 1992;33:1648–1653
  51. DeNardo GL , DeNardo SJ . Radioimmunotherapy . In:  Haynie TP editors. Nuclear Medicine (Oncology) . (ed 1). Reston, VA: Society of Nuclear Medicine; 2000;p. 39–74
  52. DeNardo GL , Kennel SJ , Siegel JA , et al.   Radiometals as payloads for radioimmunotherapy for lymphoma . Clinical Lymphoma . 2004;5(suppl):5–10
  53. Parker BA , Vassos AB , Halpern SE , et al.   Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody . Cancer Res . 1990;50(suppl):1022s–1028s

PII: S0001-2998(05)00016-4

doi: 10.1053/j.semnuclmed.2005.02.006

Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 202-211 , July 2005

Article Tools

* Image Usage & Resolution